NCT02046421: Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer |
|
|
| Completed | 1 | 31 | US | mifepristone, Mifegyne, Mifeprex, RU-38486, carboplatin, Carboplat, CBDCA, JM-8, Paraplat, Paraplatin, gemcitabine hydrochloride, dFdC, difluorodeoxycytidine hydrochloride, gemcitabine, Gemzar, laboratory biomarker analysis, pharmacological study, pharmacological studies | University of Chicago, National Cancer Institute (NCI) | Male Breast Cancer, Recurrent Breast Cancer, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer | 05/18 | 05/18 | | |
